Charting a path toward combination therapy for Alzheimer's disease

Diane Stephenson, Dan Perry, Cynthia Bens, Lisa J. Bain, Donald Berry, Michael Krams, Reisa Sperling, David Dilts, Johan Luthman, Debra Hanna, John McKew, Robert Temple, F. Owen Fields, Stephen Salloway, Russell Katz

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


It is acknowledged that progress in combined therapeutic approaches for Alzheimer's disease (AD) will require an unprecedented level of collaboration. At a meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition and the Critical Path Institute, investigators from industry, academia and regulatory agencies agreed on the need for combinatorial approaches to treating AD. The need for advancing multiple targets includes recognition for novel adaptive trial designs that incorporate existing and new biomarkers to evaluate drug effects independently and in combination. A combination trial now being planned may test drugs targeting different pathogenic pathways or multiple targets along a common pathway. Collaborations and consortia-based strategies are pivotal for success and a regulatory framework is recommended for success.

Original languageEnglish (US)
Pages (from-to)107-113
Number of pages7
JournalExpert Review of Neurotherapeutics
Issue number1
StatePublished - Jan 1 2014
Externally publishedYes


  • Alzheimer's disease
  • Co-development
  • co-development
  • collaboration
  • combination therapy
  • novel therapy

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Charting a path toward combination therapy for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this